-
Mashup Score: 0
– Highly statistically significant result observed on primary endpoint with a Win Ratio of 1.8 (p
Source: BridgeBio PharmaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
– Highly statistically significant result observed on primary endpoint with a Win Ratio of 1.8 (p
Great news from @BridgeBioPharma: they've announced "consistently positive results from phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin #amyloid cardiomyopathy (#attr-cm)" https://t.co/2KXpGCSIxC